These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 10741726)
21. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Baker SD; Heideman RL; Crom WR; Kuttesch JF; Gajjar A; Stewart CF Cancer Chemother Pharmacol; 1996; 37(3):195-202. PubMed ID: 8529278 [TBL] [Abstract][Full Text] [Related]
22. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates. Marcus L; Murphy R; Fox E; McCully C; Cruz R; Warren KE; Meyer T; McNiff E; Balis FM; Widemann BC Cancer Chemother Pharmacol; 2012 Jan; 69(1):247-52. PubMed ID: 21706317 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of pyrazoloacridine in the rhesus monkey. Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG Cancer Res; 1991 Oct; 51(20):5467-70. PubMed ID: 1913666 [TBL] [Abstract][Full Text] [Related]
24. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Berg SL; Bonate PL; Nuchtern JG; Dauser R; McGuffey L; Bernacky B; Blaney SM Clin Cancer Res; 2005 Aug; 11(16):5981-3. PubMed ID: 16115942 [TBL] [Abstract][Full Text] [Related]
25. Intrathecal administration of topotecan in nonhuman primates. Blaney SM; Cole DE; Godwin K; Sung C; Poplack DG; Balis FM Cancer Chemother Pharmacol; 1995; 36(2):121-4. PubMed ID: 7767947 [TBL] [Abstract][Full Text] [Related]
26. The plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite (OSI-420) after intravenous administration of erlotinib in non-human primates. Meany HJ; Fox E; McCully C; Tucker C; Balis FM Cancer Chemother Pharmacol; 2008 Aug; 62(3):387-92. PubMed ID: 17932674 [TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing. Mueller BU; Anderson BD; Farley MQ; Murphy R; Zuckerman J; Jarosinski P; Godwin K; McCully CL; Mitsuya H; Pizzo PA; Balis FM Antimicrob Agents Chemother; 1998 Jul; 42(7):1815-8. PubMed ID: 9661027 [TBL] [Abstract][Full Text] [Related]
28. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Stapleton SL; Reid JM; Thompson PA; Ames MM; McGovern RM; McGuffey L; Nuchtern J; Dauser R; Blaney SM Cancer Chemother Pharmacol; 2007 Mar; 59(4):461-6. PubMed ID: 16855840 [TBL] [Abstract][Full Text] [Related]
29. Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates. Patel M; McCully C; Godwin K; Balis FM J Neurooncol; 2003 Feb; 61(3):203-7. PubMed ID: 12675312 [TBL] [Abstract][Full Text] [Related]
30. Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates. Baxter PA; Thompson PA; McGuffey LM; Gibson BW; Dauser RC; Nuchtern JG; Shi C; Inloes R; Choy G; Redkar S; Blaney SM Cancer Chemother Pharmacol; 2011 Apr; 67(4):809-12. PubMed ID: 20563581 [TBL] [Abstract][Full Text] [Related]
31. Plasma and cerebrospinal fluid pharmacokinetics of intravenously administered ABT-751 in non-human primates. Cho SY; Fox E; McCully C; Bauch J; Marsh K; Balis FM Cancer Chemother Pharmacol; 2007 Sep; 60(4):563-7. PubMed ID: 17187251 [TBL] [Abstract][Full Text] [Related]
32. Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primates. Warren KE; McCully C; Dvinge H; Tjørnelund J; Sehested M; Lichenstein HS; Balis FM Cancer Chemother Pharmacol; 2008 Aug; 62(3):433-7. PubMed ID: 17960383 [TBL] [Abstract][Full Text] [Related]
33. Preclinical pharmacology of arabinosyl-5-azacytidine in nonhuman primates. Heideman RL; Balis FM; McCully C; Poplack DG Cancer Res; 1988 Aug; 48(15):4294-8. PubMed ID: 2455594 [TBL] [Abstract][Full Text] [Related]
34. Effect of P-glycoprotein modulation with cyclosporin A on cerebrospinal fluid penetration of doxorubicin in non-human primates. Warren KE; Patel MC; McCully CM; Montuenga LM; Balis FM Cancer Chemother Pharmacol; 2000; 45(3):207-12. PubMed ID: 10663638 [TBL] [Abstract][Full Text] [Related]
35. Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. Serabe BM; Murry DJ; Dauser R; Nuchtern J; Durfee J; McGuffey L; Berg S; Blaney SM Cancer Chemother Pharmacol; 1999; 43(5):415-8. PubMed ID: 10100598 [TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid pharmacokinetics and toxicology of intraventricular and intrathecal arabinosyl-5-azacytosine (fazarabine, NSC 281272) in the nonhuman primate. Heideman RL; McCully C; Balis FM; Poplack DG Invest New Drugs; 1993; 11(2-3):135-40. PubMed ID: 7505267 [TBL] [Abstract][Full Text] [Related]
37. Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme. Graham MA; Newell DR; Foster BJ; Gumbrell LA; Jenns KE; Calvert AH Cancer Res; 1992 Feb; 52(3):603-9. PubMed ID: 1732048 [TBL] [Abstract][Full Text] [Related]
38. Plasma and cerebrospinal fluid pharmacokinetics of cytosine arabinoside in dogs. Scott-Moncrieff JC; Chan TC; Samuels ML; Cook JR; Coppoc GL; DeNicola DB; Richardson RC Cancer Chemother Pharmacol; 1991; 29(1):13-8. PubMed ID: 1742843 [TBL] [Abstract][Full Text] [Related]
39. Plasma and cerebrospinal fluid pharmacokinetics of O6-benzylguanine and time course of peripheral blood mononuclear cell O6-methylguanine-DNA methyltransferase inhibition in the nonhuman primate. Berg SL; Gerson SL; Godwin K; Cole DE; Liu L; Balis FM Cancer Res; 1995 Oct; 55(20):4606-10. PubMed ID: 7553637 [TBL] [Abstract][Full Text] [Related]
40. Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates. Kilburn LB; Bonate PL; Blaney SM; McGuffey L; Nuchtern JG; Dauser R; Thompson P; Gibson BW; Berg SL Cancer Chemother Pharmacol; 2009 Jul; 64(2):335-40. PubMed ID: 19043710 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]